Markets:

Overview

News

Currencies

International

Treasuries

Mersana Therapeutics, Inc. - Common Stock (NQ:MRSN)

27.30 -0.21 (-0.76%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Mersana Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Mersana Therapeutics Inc (NASDAQ:MRSN) Reports Mixed Q3 2025 Results Amid Acquisition News ↗

November 14, 2025

Mersana Therapeutics reported mixed Q3 2025 results but the key news is its acquisition by Day One Biopharmaceuticals for $25.00 per share.

Via Chartmill

Earnings Scheduled For November 14, 2025 ↗

November 14, 2025

Via Benzinga

Mersana Therapeutics Stock Explodes Over 200% To Notch Best Day Ever As $285M Buyout Trumps Analyst Downgrades: Retail Cheers ‘Very Good Bargain’ ↗

November 14, 2025

Mersana surged even as multiple firms downgraded the stock following Day One’s acquisition agreement.

Via Stocktwits

An Overview of Mersana Therapeutics's Earnings ↗

May 14, 2025

Via Benzinga

Earnings Scheduled For November 13, 2024 ↗

November 13, 2024

Via Benzinga

Earnings Preview For Mersana Therapeutics ↗

November 12, 2024

Via Benzinga

Stay updated with the stocks that are on the move in today's after-hours session. ↗

November 13, 2025

Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

November 13, 2025

Via Benzinga

Dow Dips Over 400 Points; JD.com Posts Upbeat Q3 Results ↗

November 13, 2025

Via Benzinga

Topics Stocks

Mersana Therapeutics Earnings Preview ↗

November 13, 2025

Via Benzinga

Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout ↗

November 13, 2025

Day One Biopharmaceuticals plans to acquire Mersana Therapeutics in a deal worth up to $285 million to expand its cancer drug portfolio.

Via Benzinga

Nasdaq Down Over 150 Points; Disney Shares Fall After Q4 Results ↗

November 13, 2025

Via Benzinga

Mersana Catapults 200% On Day One Bio's Surprise Buyout ↗

November 13, 2025

Shares of Mersana Therapeutics catapulted early Thursday after Day One Biopharmaceuticals agreed to buy it.

Via Investor's Business Daily

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

November 13, 2025

Via Benzinga

MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal ↗

November 13, 2025

The upfront purchase price of $25 alone represents a premium of 182% from Mersana’s closing price on Wednesday.

Via Stocktwits

Mersana Misses Fiscal Q2 Revenue Target ↗

August 13, 2025

Via The Motley Fool

A Look at Mersana Therapeutics's Upcoming Earnings Report ↗

August 12, 2025

Via Benzinga

What's going on in today's session ↗

July 24, 2025

Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top gainers and losers in today's session.

Via Chartmill

Thursday's session: gap up and gap down stocks ↗

July 24, 2025

Today's session on Thursday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

Earnings Scheduled For August 13, 2025 ↗

August 13, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

June 30, 2025

Via Benzinga

Top movers in Thursday's after hours session ↗

April 24, 2025

The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Via Chartmill

Earnings Scheduled For March 3, 2025 ↗

March 03, 2025

Via Benzinga

Earnings Scheduled For May 15, 2025 ↗

May 15, 2025

Via Benzinga

This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

February 06, 2025

Via Benzinga

Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday? ↗

January 10, 2025

Mersana shares Phase 1 data on Emi-Le for TNBC and details FDA's Fast Track status for XMT-1660 in advanced HER2-low breast cancer.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 13, 2024

Via Benzinga

Why BloomZ Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket ↗

October 10, 2024

Via Benzinga

MRSN Stock Earnings: Mersana Therapeutics Misses EPS, Misses Revenue for Q2 2024 ↗

August 13, 2024

MRSN stock results show that Mersana Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Via InvestorPlace

MRSN Stock Earnings: Mersana Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗

May 09, 2024

MRSN stock results show that Mersana Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.